US2016168575A1PendingUtilityA1

Antisense design

66
Assignee: ROCHE INNOVATION CT COPENHAGEN ASPriority: Nov 18, 2002Filed: Oct 13, 2015Published: Jun 16, 2016
Est. expiryNov 18, 2022(expired)· nominal 20-yr term from priority
Inventors:Signe M. ChristensenNikolaj Dam MikkelsenMiriam FriedenHenrik Frydenlund HansenTroels KochDaniel Sejer PedersenChristoph RosenbohmCharlotte Albaek ThrueMajken Westergaard
C12N 2310/315C12N 2320/30C12N 2320/51C12N 15/111C07H 21/00C07H 19/06C12N 15/113C12N 2310/11C12N 2310/3231C07H 21/04C12N 2310/344C07H 19/04C07H 21/02C12N 2310/341C12N 15/1137A61K 31/7088C07H 19/16
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising a therapeutically active antisense oligonucleotide construct which (i) comprises at least one locked nucleic acid unit selected from the group consisting of amino-LNA and thio-LNA and derivatives thereof: or (ii) comprises at least two consecutively located locked nucleotide units of which at least one is selected from the group consisting of alpha-L-oxy-LNA and derivatives thereof. 
     
     
         2 .- 42 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.